SkinBioTherapeutics Plc – LSE:SBTX.L
SkinBioTherapeutics stock price today
SkinBioTherapeutics stock price monthly change
SkinBioTherapeutics stock price quarterly change
SkinBioTherapeutics stock price yearly change
SkinBioTherapeutics key metrics
Market Cap | 39.63M |
Enterprise value | 2.21B |
P/E | -9.25 |
EV/Sales | N/A |
EV/EBITDA | -1770.68 |
Price/Sales | N/A |
Price/Book | 8.23 |
PEG ratio | 0.12 |
EPS | -0.02 |
Revenue | 249.60K |
EBITDA | -4.87M |
Income | -4.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1953.1% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSkinBioTherapeutics stock price history
SkinBioTherapeutics stock forecast
SkinBioTherapeutics financial statements
| Dec 2021 | 10.97K | -537.46K | -4897.6% |
|---|---|---|---|
| Dec 2022 | 76.98K | -1.28M | -1669.16% |
| Jun 2023 | 55.07K | -1.55M | -2814.76% |
| Dec 2023 | 106.57K | -1.33M | -1252.45% |
| Dec 2021 | 4612924 | 451.29K | 9.78% |
|---|---|---|---|
| Sep 2022 | 1988312 | 692.97K | 34.85% |
| Dec 2022 | 1988312 | 775.79K | 39.02% |
| Dec 2023 | 4211397 | 560.33K | 13.31% |
| Dec 2021 | -1.40M | -41.53K | -12.28K |
|---|---|---|---|
| Dec 2022 | -993.92K | -27.19K | -17.82K |
| Jun 2023 | -1.65M | -138.08K | 2.33M |
| Dec 2023 | -1.36M | -76.48K | 2.97M |
SkinBioTherapeutics alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Mar 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 11 |
SkinBioTherapeutics other data
| Insider | Compensation |
|---|---|
Mr. Stuart John Ashman (1967) Chief Executive Officer & Executive Director | $328,820 |
-
What's the price of SkinBioTherapeutics stock today?
One share of SkinBioTherapeutics stock can currently be purchased for approximately $42.
-
When is SkinBioTherapeutics's next earnings date?
Unfortunately, SkinBioTherapeutics's (SBTX.L) next earnings date is currently unknown.
-
Does SkinBioTherapeutics pay dividends?
No, SkinBioTherapeutics does not pay dividends.
-
How much money does SkinBioTherapeutics make?
SkinBioTherapeutics has a market capitalization of 39.63M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1516.71% to 1.21M US dollars.
-
What is SkinBioTherapeutics's stock symbol?
SkinBioTherapeutics Plc is traded on the LSE under the ticker symbol "SBTX.L".
-
What is SkinBioTherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of SkinBioTherapeutics?
Shares of SkinBioTherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are SkinBioTherapeutics's key executives?
SkinBioTherapeutics's management team includes the following people:
- Mr. Stuart John Ashman Chief Executive Officer & Executive Director(age: 58, pay: $328,820)
-
How many employees does SkinBioTherapeutics have?
As Jul 2024, SkinBioTherapeutics employs 11 workers.
-
When SkinBioTherapeutics went public?
SkinBioTherapeutics Plc is publicly traded company for more then 8 years since IPO on 5 Apr 2017.
-
What is SkinBioTherapeutics's official website?
The official website for SkinBioTherapeutics is skinbiotherapeutics.com.
-
How can i contact SkinBioTherapeutics?
SkinBioTherapeutics can be reached via phone at +44 161 468 2760.
SkinBioTherapeutics company profile:
SkinBioTherapeutics Plc
skinbiotherapeutics.comLSE
11
Biotechnology
Healthcare
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Newcastle upon Tyne, NE4 5TF
:
ISIN: GB00BF33H870
CUSIP: G7208A105
